HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study

Background and Aims: Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg loss with 48- and 96-week Peg-IFN alfa-2a in ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Peng, Shang, Jia, Zhang, Wenhong, Gong, Guozhong, Li, Yongguo, Chen, Xinyue, Jiang, Jianning, Xie, Qing, Dou, Xiaoguang, Sun, Yongtao, Li, Yufang, Liu, Yingxia, Liu, Guozhen, Mao, Dewen, Chi, Xiaoling, Tang, Hong, Li, Xiaoou, Xie, Yao, Chen, Xiaoping, Jiang, Jiaji, Zhao, Ping, Hou, Jinlin, Gao, Zhiliang, Fan, Huimin, Ding, Jiguang, Zhang, Dazhi, Ren, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862996/
https://www.ncbi.nlm.nih.gov/pubmed/29577029
http://dx.doi.org/10.14218/JCTH.2017.00072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862996/
https://www.ncbi.nlm.nih.gov/pubmed/29577029
http://dx.doi.org/10.14218/JCTH.2017.00072

Ejemplares similares